Past, present, and future of long-term treatment for hepatitis B virus
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Broquetas, Teresa
- dc.contributor.author Carrión Rodríguez, José Antonio
- dc.date.accessioned 2024-06-04T06:20:37Z
- dc.date.available 2024-06-04T06:20:37Z
- dc.date.issued 2023
- dc.description.abstract The estimated world prevalence of hepatitis B virus (HBV) infection is 316 million. HBV infection was identified in 1963 and nowadays is a major cause of cirrhosis and hepatocellular carcinoma (HCC) despite universal vaccination programs, and effective antiviral therapy. Long-term administration of nucleos(t)ide analogues (NA) has been the treatment of choice for chronic hepatitis B during the last decades. The NA has shown a good safety profile and high efficacy in controlling viral replication, improving histology, and decreasing the HCC incidence, decompensation, and mortality. However, the low probability of HBV surface antigen seroclearance made necessary an indefinite treatment. The knowledge, in recent years, about the different phases of the viral cycle, and the new insights into the role of the immune system have yielded an increase in new therapeutic approaches. Consequently, several clinical trials evaluating combinations of new drugs with different mechanisms of action are ongoing with promising results. This integrative literature review aims to assess the knowledge and major advances from the past of hepatitis B, the present of NA treatment and withdrawal, and the future perspectives with combined molecules to achieve a functional cure.
- dc.format.mimetype application/pdf
- dc.identifier.citation Broquetas T, Carrión JA. Past, present, and future of long-term treatment for hepatitis B virus. World J Gastroenterol. 2023 Jul 7;29(25):3964-83. DOI: 10.3748/wjg.v29.i25.3964
- dc.identifier.doi http://dx.doi.org/10.3748/wjg.v29.i25.3964
- dc.identifier.issn 1007-9327
- dc.identifier.uri http://hdl.handle.net/10230/60336
- dc.language.iso eng
- dc.publisher Baishideng Publishing Group
- dc.relation.ispartof World J Gastroenterol. 2023 Jul 7;29(25):3964-83
- dc.rights © The Author(s) 2023. This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by-nc/4.0/
- dc.subject.keyword Antigen
- dc.subject.keyword Antiviral agents
- dc.subject.keyword Drug development
- dc.subject.keyword Functional cure
- dc.subject.keyword Hepatitis B
- dc.subject.keyword Therapy
- dc.title Past, present, and future of long-term treatment for hepatitis B virus
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion